Trials / Completed
CompletedNCT00419393
Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures
An Open-label, Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Treatment of Partial-onset Seizures
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 190 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 12 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To provide continued treatment of Keppra XR (Levetiracetam XR) and to assess the long term safety of Keppra XR in subjects with partial onset seizures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Keppra XR (Levetiracetam XR) | 500 mg tablets, 1000 - 3000 mg/day, flexible dosing for duration of the study (planned: approximately 6 months-3 years). |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2010-03-01
- Completion
- 2010-03-01
- First posted
- 2007-01-08
- Last updated
- 2014-09-05
- Results posted
- 2011-07-13
Locations
35 sites across 4 countries: United States, Mexico, Poland, Russia
Source: ClinicalTrials.gov record NCT00419393. Inclusion in this directory is not an endorsement.